Complex Pharmacological Therapy of Ovarian Cancer
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Wu, Ching-Hsuan | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Megyeri, Attila | |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2022-08-18T08:46:16Z | |
| dc.date.available | 2022-08-18T08:46:16Z | |
| dc.date.created | 2022 | |
| dc.description.abstract | Ovarian cancer is malicious, due to late presentation and advanced stage diagnosis. The first-line treatment of all types of ovarian cancer is primary debulking surgery, in which maximal cytoreduction should be achieved, and is usually followed by adjuvant chemotherapy. However, relapses and resistance to chemotherapy often occur, thus maintenance therapy and alternative agents such as targeted therapy or immunotherapy are often required. | hu_HU |
| dc.description.corrector | hbk | |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 51 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/336575 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Ovarian cancer | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány::Farmakológia | hu_HU |
| dc.title | Complex Pharmacological Therapy of Ovarian Cancer | hu_HU |